Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan.

Cancers (Basel) · 2025 · PMC12070933 · PMID 40361315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Discussion In this real-world study of patients with transplant-ineligible NDMM in Japan, those who received 1L DRd showed a trend toward an improvement in OS from the time of MM diagnosis by approximately 34% compared with 2L DRd (inverse HR of 0.658; 95% CI: 0.278, 1.563).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.